Onatasertib

DB12570InvestigationalSmall molecule

Onatasertib (CC-223) has been used in trials studying the treatment and basic science of Multiple Myeloma, Glioblastoma Multiforme, HepatoCellular Carcinoma, Non-small Cell Lung Cancer, and Diffuse Large B-Cell Lymphoma, among...

Mechanism: Pharmacologically active on Serine/threonine-protein kinase mTOR
Curator reviewed
Formula / weight: C₂₁H₂₇N₅O₃ · 397.479 g/mol (avg)
Code names: CC-223

Resolves to

Compound

UNIII8RA3543SYCAS1228013-30-6ChEMBLCHEMBL3586404PubChem58298316

Structure

InChIKeyUFKLYTOEMRFKAD-SHTZXODSSA-NSMILESCO[C@H]1CC[C@@H](CC1)N1C(=O)CNC2=C1N=C(C=N2)C1=CN=C(C=C1)C(C)(C)O

Targets

P42345MTOR

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Onatasertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account